**Scaffolds and Matrices**

[86] Undale, A., et al., *Induction of fracture repair by mesenchymal cells derived from human*

[87] Locke, M., V. Feisst, and P.R. Dunbar, *Concise review: human adipose-derived stem cells:*

[88] Liu, W., et al., *Genetic and epigenetic X-chromosome variations in a parthenogenetic human*

[89] Noisa, P. and R. Parnpai, *Technical challenges in the derivation of human pluripotent cells.*

[90] Anastasia, L., et al., *Cell reprogramming: expectations and challenges for chemistry in stem cell biology and regenerative medicine.* Cell Death Differ, 2010. 17(8): p. 1230-7.

[91] Takahashi, K. and S. Yamanaka, *Induction of pluripotent stem cells from mouse embryonic*

[92] Kamata, M., et al., *Live cell monitoring of hiPSC generation and differentiation using differ‐*

[93] Gunaratne, P.H., *Embryonic stem cell microRNAs: defining factors in induced pluripotent (iPS) and cancer (CSC) stem cells?* Curr Stem Cell Res Ther, 2009. 4(3): p. 168-77.

[94] Hockemeyer, D., et al., *Genetic engineering of human pluripotent cells using TALE nucle‐*

[95] Hoogduijn, M.J., et al., *Immunological aspects of allogeneic and autologous mesenchymal*

[96] Drukker, M., *Immunological considerations for cell therapy using human embryonic stem*

[97] Drukker, M., *Recent advancements towards the derivation of immune-compatible patientspecific human embryonic stem cell lines.* Semin Immunol, 2008. 20(2): p. 123-9.

[98] Zhao, T., et al., *Immunogenicity of induced pluripotent stem cells.* Nature, 2011.

[99] FDA, *http://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/Approved‐*

*and adult fibroblast cultures by defined factors.* Cell, 2006. 126(4): p. 663-76.

*ential expression of endogenous microRNAs.* PLoS One, 2010. 5(7): p. e11834.

*separating promise from clinical need.* Stem Cells, 2011. 29(3): p. 404-11.

*embryonic stem cell line.* J Assist Reprod Genet, 2011. 28(4): p. 303-13.

*embryonic stem cells or bone marrow.* J Orthop Res, 2011.

Stem Cells Int, 2011. 2011: p. 907961.

218 Regenerative Medicine and Tissue Engineering

*ases.* Nat Biotechnol, 2011.

*cell derivatives.* 2008.

474(7350): p. 212-5.

*Products/default.htm.*

*stem cell therapies.* Hum Gene Ther, 2011.
